Harnessing AI to Accelerate Global Sepsis Trials
An Australian start-up is using ARM Hub's Data and AI-as-a-Service to save lives from sepsis around the world.
Challenge
Microbio is a start-up biotechnology company with an innovative diagnostic assay, InfectID™-BSI that can detect 26 sepsis-causing pathogens directly from whole blood in under three hours. Global clinical trials are required to commercialise this therapy, and the trials generate large amounts of complex data requiring intensive analytics.
To efficiently execute these trials, Microbio need to access highly experienced data scientists and, if successful, will need to transform itself from being a scientific enterprise into a data-intensive manufacturing business. Investment will be required for each stage of this development.
Microbio has already secured distribution agreements in India, Indonesia, the Middle East and North Africa for this potentially life-saving sepsis therapy.
what the arm hub did
The company leveraged the ARM Hub’s Data and AI-as-a-Service to implement a highly efficient and scalable data architecture using a Databricks’ AI Lakehouse technology. This architecture allows them to seamlessly manage and govern their clinical trial data from multiple sites.
The project involved a co-design workshop that developed a Data and AI Roadmap that would deliver global clinical trials, establish the business’ future data foundations, and support data sharing. The outcome was a clear pathway for a cost-effective and sustainable solution that did not dilute company equity or IP ownership. The approach incorporated Large Language Models as AI tools enabling non-tech staff to conduct internal data analysis and manage the clinical trials from different locations across the globe safely and responsibly.
As the project progresses, Microbio is poised to further reduce clinical trial timelines, enhance trial accuracy, and better manage diverse datasets, ultimately supporting the company’s goal of expanding InfectID™-BSI globally.
Microbio received competitive matched funding through the Biomedical AI Sprints Accelerator (BASA) and the Scaleup Manufacturing for Female Founders Accelerator. This is an outcome of the Australian Government supported ARM Hub AI Adopt program with partners MTP and the Queensland Government.
